The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.
 
Jayesh Desai
Consulting or Advisory Role - Amgen; BeiGene; Bionomics; Eisai; Lilly; Novartis
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Mark Voskoboynik
No Relationships to Disclose
 
Ben Markman
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - BeiGene
 
Jeannie Hou
Employment - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Dewan Zeng
Employment - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Tarek Meniawy
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca; MedImmune
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech